Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat.com Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsBy Nathan Reiff. Date Posted: 3/12/2026. 
What You Need to Know - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often take a niche approach, developing medicines that target specific cancer types with dedicated mechanisms. Fortunately, a number of promising treatments have shown significant potential—and with that comes the possibility of substantial sales. Two smaller biotech companies are experiencing strong share price momentum thanks to their leading oncology medicines. Besides offering promising therapeutic potential, these drugs may help the firms move toward greater stability and, potentially, long-term profitability. In both cases, considerable challenges remain, making these typical biotech investments—high-risk ventures that may offer outsized rewards to investors willing to take a chance. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. Get the name and ticker of Louis Navellier's #1 AI stock free Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% in a week when the S&P 500 slipped about 1%. That added to IOVA's year-to-date (YTD) performance, which has seen shares more than double. Still, with a consensus price target of $8.88, Wall Street expects more from IOVA shares—that target suggests roughly 71% more upside could remain. The main catalyst for Iovance's price movement is its lead therapy, Amtagvi, a T‑cell immunotherapy for certain melanomas. Amtagvi was approved in the U.S. for melanoma in 2024 and is gaining momentum in sales, with additional approvals possible in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's interleukin-2 (IL‑2) immunotherapy, management believes Amtagvi has the potential to exceed $1 billion in peak U.S. sales. Amtagvi's potential may extend beyond melanoma: the drug received FDA Fast Track designation for non-small cell lung cancer and may be effective against other cancers as well. Some of Iovance's outperformance this year stemmed from its Q4 2025 earnings report, issued in late February, in which the company posted better-than-expected results—narrower-than-forecast losses per share—and $5 million in revenue. For the full year, revenue rose about 30% year-over-year (YOY). Iovance remains a relatively small biotech (approximately $2 billion market cap), and despite the rally, analysts are cautious: about half of its roughly a dozen ratings are either Hold or Sell. Risks remain high; beyond the usual small‑biotech caveats, Amtagvi's manufacturing process leaves the company exposed. The therapy is personalized, costly, and complex to manufacture, which could limit Iovance's ability to generate consistent profits even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug Although ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, its YTD performance dwarfs Iovance's. IBRX shares are up nearly 300% in 2026 so far, and that may not be the end of the run. Analysts have a consensus price target of $13.60, roughly 70% above the stock's current price even after the recent surge. ImmunityBio's leading product is Anktiva, a treatment for certain bladder cancers. In February, shares jumped after the E.U.'s regulator granted conditional marketing authorization—the latest in a string of approvals worldwide. Anktiva is driving the firm's revenue growth, producing $113 million in sales last year, a roughly 700% year-over-year increase. Like Amtagvi, Anktiva may be effective against other cancer types; ImmunityBio is actively exploring additional indications. Despite its rapid rise over recent quarters, IBRX remains a speculative and risky investment. ImmunityBio reported a sizeable full-year net loss of $351 million for 2025 as R&D expenses continue to climb. Wall Street analysts appear more bullish on ImmunityBio than on Iovance: six of seven analysts rate the shares a Buy or equivalent.
| 
